Project Grant R37CA303094
Award Date 9/12/25
Completion Date 8/31/30
Dollars Obligated $818K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Cancer Institute awarded a $673,096 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The grant is designed to improve cancer and mental health care delivery for adults affected by serious mental illness (SMI) across a cancer center network. The project aims to develop and evaluate the BRIDGE model of person-centered collaborative care, which...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $599,339 to the University of Miami to conduct a randomized clinical trial evaluating the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) for improving quality of life, psychological distress, symptom burden, coping, and self-efficacy in hematopoietic stem cell transplant survivors living with chronic graft-versus-host disease. The study aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $818,625 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct a randomized trial evaluating cardioprotective strategies for patients with diffuse large B-cell lymphoma (DLBCL) who have pre-existing cardiomyopathy or prior anthracycline exposure. The primary objective is to determine whether the infusional cardioprotective strategies of dexrazoxane or liposomal doxorubicin...
- The National Institutes of Health's National Cancer Institute awarded a $662,516 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the federal grant program "Cancer Treatment Research" (CFDA 93.395). The grant, awarded on March 11, 2025, supports a 5-year research project to evaluate how fractionated radiation therapy affects the tumor microenvironment and impacts the delivery of long-circulating chemotherapy agents. The...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $706,669.00 to conduct a placebo-controlled, phase II randomized clinical trial to evaluate the effects of photobiomodulation therapy (PBMT) on chronic lymphedema in head and neck cancer survivors. The trial aims to assess the impact of PBMT on the severity of external and internal lymphedema, as well as its effects on symptom burden and functional impairment. The...
- This $858,166 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is for a randomized trial of a targeted palliative care intervention for patients with metastatic breast cancer. The grant supports a 5-year study to be conducted by The General Hospital Corporation (Massachusetts General Hospital) to improve documentation of end-of-life care preferences, delivery of end-of-life care, and patient-reported outcomes for this patient population....
- This Project Grant award of $306,798 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop an artificial intelligence-based system to accurately identify malignant lymph nodes. The key objectives are to: Create a lymph node segmentation model to enable extraction of radiomic features critical for malignancy classification. Develop both cloud-based and standalone desktop deployment options for the classification model to...
- The Department of Health and Human Services' National Cancer Institute awarded a $644,034 Project Grant on March 11, 2025 under the Cancer Treatment Research (CFDA 93.395) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant is for the development of a "scintillating nanoparticle drug depot (SCIDD) platform" that uses nanoparticles to convert X-ray energy into light, which can then release potent and tumor-penetrating...
- This federal Project Grant award of $714,110.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research by New York University School of Medicine to translate insights in follicular lymphoma for improved diagnosis and classification. The research aims to identify reliable predictive biomarkers to guide frontline risk stratification and treatment for high-risk follicular lymphoma patients, who face a poor prognosis due to early disease...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $620,820.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of the transcription factor CREB5 in driving immune therapy resistance in cancer. The research aims to: 1) understand the molecular mechanisms governing CREB5 regulation and transcription, 2) identify CREB5-interacting proteins that drive collagen matrix...